Additional role for Juergen Eckhardt at Bayer

25 August 2023

Germany’s Bayer (BAYN: DE) has announced that Dr Juergen Eckhardt is to be the new head of business development and licensing / open innovation (BDL/OI) of its Pharmaceuticals Division effective September 1, 2023.

He will join the Pharmaceuticals executive committee and report to Stefan Oelrich, a member of the board of management, Bayer AG, and president of the company's Pharmaceuticals Division.

At the same time, Dr Eckhardt will continue to lead Leaps by Bayer, the company’s impact investment arm and in that role continue to report to Bill Anderson, chairman of the board of management of Bayer AG.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK